You are viewing: Rest Of Latin America Oral Proteins & Peptides Market analysis

The Rest Of Latin America Oral Proteins & Peptides Market was valued at $137.8 Million in 2025 and projected to reach to $213.7 Million by 2030, representing a compound annual growth rate of 9.2%. Rest Of Latin America's oral proteins & peptides market demonstrates steady expansion driven by enhanced healthcare infrastructure and growing pharmaceutical sector investments.

Rest Of Latin America Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Latin America Oral Proteins & Peptides Market Trends and Insights

  • This growth trajectory reflects increasing healthcare investments and rising demand for innovative therapeutic delivery systems across the region.
  • Rest Of Latin America is positioning itself as an emerging market for oral peptide formulations, driven by improving healthcare infrastructure and growing patient awareness of advanced treatment options. The market in Rest Of Latin America is characterized by a 9.2% compound annual growth rate, significantly outpacing some mature markets but reflecting the region's developing pharmaceutical landscape.
  • Rest Of Latin America's pharmaceutical sector is increasingly adopting oral protein and peptide technologies to address chronic disease management and improve patient compliance.
  • Between 2025 and 2030, Rest Of Latin America is expected to see accelerated adoption of these therapies, supported by regulatory harmonization efforts and expanding manufacturing capabilities within the region..

Key Market Statistics

  • CAGR (2025-2030) 9.2% CAGR
  • Market Size, 2025 ~USD 137.8 Million
  • Forecast, 2030 ~USD 213.7 Million
  • Country Rest Of Latin America

Rest Of Latin America Oral Proteins & Peptides Market Overview

Market Valuation Growth :

Rest Of Latin America's oral proteins & peptides market is valued at USD 137.8 million in 2025, with projections reaching USD 213.7 million by 2030, representing a robust 9.2% CAGR over the forecast period.

Healthcare Investment Surge :

Increasing healthcare investments across Rest Of Latin America are driving adoption of innovative oral protein and peptide therapeutics, positioning the region as a key growth market for advanced delivery systems.

Emerging Market Potential :

Rest Of Latin America is establishing itself as an emerging hub for oral proteins & peptides, with growing pharmaceutical infrastructure and rising demand for non-invasive therapeutic alternatives among healthcare providers.

Therapeutic Delivery Innovation :

The region is experiencing increased demand for innovative oral delivery systems that enhance bioavailability and patient compliance, driving market expansion and attracting pharmaceutical manufacturers to the Rest Of Latin America market.

Rest Of Latin America Oral Proteins & Peptides Market Dynamics

  • The region's 9.2% CAGR reflects increasing adoption of oral protein therapeutics as healthcare systems prioritize patient-centric solutions and non-invasive treatment options.
  • Rising prevalence of chronic diseases and improved access to advanced medications are key growth catalysts. Looking ahead, Rest Of Latin America is poised to capture significant market share as pharmaceutical companies expand distribution networks and regulatory frameworks become more favorable.
  • Collaborations between local healthcare providers and international manufacturers will accelerate market penetration.
  • The region's emerging status combined with growing middle-class healthcare spending positions it as a strategic market for oral protein and peptide innovations through 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Rest Of Latin America's oral proteins & peptides market is valued at USD 137.8 million in 2025 and will reach USD 213.7 million by 2030, representing a 9.2% CAGR.
    • Rest Of Latin America is emerging as a key growth market driven by improving healthcare infrastructure and increasing pharmaceutical innovation adoption.
    • Rest Of Latin America's market growth is supported by rising chronic disease prevalence and enhanced patient access to advanced therapeutic options.
    • Rest Of Latin America's regulatory environment and manufacturing expansion are critical enablers for sustained market development through 2030.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Rest Of Latin America Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    Target Audience

    • Pharmaceutical Manufacturers : Pharmaceutical companies seeking to expand oral protein & peptide portfolios in Rest Of Latin America need detailed market intelligence to identify growth opportunities, assess competitive positioning, and optimize regional launch strategies.
    • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in Rest Of Latin America's emerging pharmaceutical sector require comprehensive market data to assess growth potential, valuation benchmarks, and risk-adjusted returns in oral therapeutics.
    • Biotech & Contract Manufacturing Organizations : CMOs and biotech firms developing oral protein delivery technologies need Rest Of Latin America market insights to identify partnership opportunities, licensing potential, and manufacturing demand forecasts in the region.
    • Healthcare Policy & Government Agencies : Government health ministries and regulatory bodies in Rest Of Latin America require market analysis to inform healthcare policy, reimbursement frameworks, and pharmaceutical procurement strategies aligned with regional growth trends.
    • Medical Device & Diagnostics Companies : Companies in adjacent healthcare sectors need Rest Of Latin America oral proteins market data to identify cross-selling opportunities, complementary product development, and strategic partnerships within the region's expanding therapeutic ecosystem.

    Key Companies in the Rest Of Latin America Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations specific to Rest Of Latin America with detailed 2025-2030 projections, enabling accurate budget allocation and investment planning for regional expansion strategies.
    • Competitive Landscape Intelligence : Gain insights into Rest Of Latin America's pharmaceutical competitive dynamics, including key players, market share distribution, and emerging competitors positioning themselves in this high-growth emerging market.
    • Regulatory & Healthcare Infrastructure Analysis : Understand Rest Of Latin America's unique regulatory environment, healthcare system structure, and reimbursement policies that directly impact oral protein & peptide market adoption and commercialization strategies.
    • Growth Driver Identification : Identify region-specific growth catalysts including healthcare investment trends, disease prevalence patterns, and patient demand drivers unique to Rest Of Latin America's market dynamics.
    • Strategic Market Entry Guidance : Develop targeted go-to-market strategies for Rest Of Latin America with actionable recommendations on distribution channels, partnership opportunities, and localization requirements for successful market penetration.

    Frequently asked questions

    What is the current market size of oral proteins & peptides in Rest Of Latin America?

    Rest Of Latin America's oral proteins & peptides market is valued at USD 137.8 million in 2025.

    What is the projected market size for Rest Of Latin America by 2030?

    Rest Of Latin America's oral proteins & peptides market is projected to reach USD 213.7 million by 2030.

    What is the CAGR for Rest Of Latin America's oral proteins & peptides market?

    Rest Of Latin America's oral proteins & peptides market is expected to grow at a compound annual growth rate of 9.2% from 2025 to 2030.

    What factors are driving growth in Rest Of Latin America's market?

    Rest Of Latin America's market growth is driven by improving healthcare infrastructure, rising chronic disease prevalence, regulatory harmonization, and expanding pharmaceutical manufacturing capabilities.

    How does Rest Of Latin America's growth rate compare to global trends?

    Rest Of Latin America's 9.2% CAGR is lower than the global market CAGR of 22.1%, reflecting the region's developing market status and gradual adoption of oral protein and peptide technologies.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status